Eiger BioPharmaceuticals, Inc.
EIGR
Rang în acțiuni
#36384
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Preț acțiune
$1.73
Ultima sincronizare: 2025-06-17
Capitalizare de piață
$2.55M
Schimbare (1 zi)
-0.29%
Schimbare (1 an)
-79.71%
Țară
US
Tranzacționează Eiger BioPharmaceuticals, Inc. (EIGR)
Categorie
Healthcare
Istoric al prețului acțiunii pentru Eiger BioPharmaceuticals, Inc. (EIGR)
Cel mai mare preț de închidere: $8.50 pe 2024-10-01
Cel mai mic preț de închidere: $3.75K pe 2014-01-01
Cel mai mic preț de închidere: $3.75K pe 2014-01-01
Istoric al prețului acțiunii pentru Eiger BioPharmaceuticals, Inc. din 2014 până în 2026
Evoluția anuală a prețului acțiunii
| An | Performanță |
|---|---|
| 2024 | 8.23% |
| 2023 | -86.28% |
| 2022 | -65.86% |
| 2021 | -43.34% |
| 2020 | -27.82% |
| 2019 | 28.55% |
| 2018 | -15.78% |
| 2017 | 8.44% |
| 2016 | -45.90% |
| 2015 | -91.44% |
| 2014 | 0.00% |
Prețul acțiunii pentru companii similare sau concurente
| Companie | Preț acțiune | Variație 1an% | Țara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.21 | 7.77% |
CH
|
